Inhibikase Therapeutics, INC 8-K filings

Inhibikase Therapeutics announced Q2 2026 results, highlighting progress in its Phase 3 PAH study, positive early data for IKT-001, and a $50 million capital raise.

Inhibikase Therapeutics issued a pre-funded warrant to RA Capital Healthcare Fund, L.P. in exchange for 18,030,000 shares of common stock.

Inhibikase Therapeutics announced that the FDA has granted Orphan Drug Designation to its lead candidate, IKT-001, for the treatment of Pulmonary Arterial Hypertension (PAH).

Inhibikase Therapeutics announced the sale of $50 million in common stock through its at-the-market facility to RA Capital Management.

Inhibikase Therapeutics stockholders approved key proposals at the 2026 Annual Meeting, including an increase in equity incentive shares and officer liability limitation.

Inhibikase Therapeutics reported Q1 2026 financial results, highlighting the enrollment of the first patient in its pivotal IMPROVE-PAH Phase 3 study for Pulmonary Arterial Hypertension and progress in securing global regulatory approvals.

Inhibikase Therapeutics has officially commenced patient enrollment for its pivotal Phase 3 IMPROVE-PAH trial evaluating IKT-001 for Pulmonary Arterial Hypertension.

Inhibikase Therapeutics announced the initiation of its global pivotal Phase 3 IMPROVE-PAH study for IKT-001 and reported full-year 2025 financial results, including a significant increase in cash reserves.

Inhibikase Therapeutics, Inc. filed a prospectus supplement to offer and sell up to $185 million in common stock through its existing at-the-market offering program.

Inhibikase Therapeutics, Inc. announced an underwritten public offering of common stock and pre-funded warrants, aiming to raise approximately $93.6 million to fund its IKT-001 Phase 3 clinical trial in PAH.

Inhibikase Therapeutics, Inc. announced it will advance its IKT-001 drug directly to a global pivotal Phase 3 clinical study for Pulmonary Arterial Hypertension (PAH) in Q1 2026, following FDA feedback.

Inhibikase Therapeutics reported a wider net loss for the third quarter of 2025 while announcing plans to initiate its Phase 2b IMPROVE-PAH clinical trial for IKT-001 in the fourth quarter.

Inhibikase Therapeutics announced its second quarter 2025 financial results, reporting an increased net loss, while confirming plans to initiate a pivotal Phase 2b clinical study for its lead PAH therapeutic, IKT-001, in the second half of 2025.

Inhibikase Therapeutics, Inc. announced that its stockholders approved the election of two Class II directors, the ratification of CohnReznick LLP as its independent auditor, and an amendment to its 2020 Equity Incentive Plan at the 2025 Annual Meeting.

Inhibikase Therapeutics announced its Q1 2025 financial results, reporting a net loss of $13.7 million and highlighting progress in advancing IKT-001 for pulmonary arterial hypertension (PAH).

Inhibikase Therapeutics appoints David McIntyre as CFO, effective April 14, 2025, to leverage his expertise in financial strategy and life sciences capital markets.

Inhibikase Therapeutics reported its 2024 financial results, highlighting a strategic shift towards advancing IkT-001 into a late-stage clinical trial for pulmonary arterial hypertension (PAH).

Inhibikase Therapeutics acquires CorHepta Pharmaceuticals for $15 million in stock, appoints Chris Cabell as President and Head of R&D, John Adams as Chief Scientific Officer, and Vincent Aurentz to the Board of Directors.

Inhibikase Therapeutics appoints Mark Iwicki as CEO, succeeding founder Milton H. Werner, and names Amit Munshi as Board Chair, effective February 14, 2025.

Inhibikase Therapeutics reports Phase 2 trial results for risvodetinib in Parkinson's disease, meeting its primary safety endpoint but showing mixed efficacy results.

Inhibikase Therapeutics has increased its authorized common stock shares to 500 million and eliminated a supermajority voting requirement for certain amendments.

Inhibikase Therapeutics has terminated its At-the-Market Offering Agreement with H.C. Wainwright & Co., effective December 11, 2024.

Inhibikase Therapeutics closed a $110 million private placement, appointed four new board members, and is advancing its IkT-001Pro drug into a late-stage clinical trial for Pulmonary Arterial Hypertension.

Inhibikase Therapeutics has announced a $110 million private placement to fund a Phase 2b trial for its pulmonary arterial hypertension (PAH) drug, IkT-001Pro.

Inhibikase Therapeutics is developing IkT-001Pro, a prodrug of imatinib, for pulmonary arterial hypertension (PAH), with a Phase 2 interim safety readout anticipated in late 2025 or early 2026.

Inhibikase Therapeutics' stockholders approved the issuance of common stock purchase warrants related to a private placement and warrant inducement at a special meeting held on August 5, 2024.

Inhibikase Therapeutics held its 2024 annual meeting, electing a director, ratifying its accounting firm, and approving an increase in authorized shares, while failing to pass a proposal to amend its certificate of incorporation.

Inhibikase Therapeutics has announced a registered direct offering and warrant inducement expected to generate approximately $4 million in gross proceeds.

Inhibikase Therapeutics is facing a $1.625 million arbitration claim for alleged breach of contract while also progressing its clinical trials and seeking additional funding.

Inhibikase Therapeutics announced progress in its clinical trials, including nearing completion of enrollment for its Phase 2 trial for Parkinson's disease and advancements in its IkT-001Pro program.